October 2026

aod-9604 dropped off the fda's watchlist this spring — and the search traffic followed

AOD-9604 monthly searches are running at roughly 22,000 in October 2026 — a number that has been climbing steadily as GLP-1 prices stay elevated and people look for cheaper alternatives. In April 2026, the compound dropped off the FDA's Category 2 interim 503A bulks list. That's the news that moved through wellness newsletters and optimization-clinic marketing materials. What those sources mostly didn't include: the FDA removed AOD-9604 because its bulks-list nomination was withdrawn — not because the compound received a safety clearance or moved toward approval. Category 2 existed specifically to flag substances that couldn't be legally compounded under Section 503A while their inclusion was under review. When the nomination for AOD-9604 was withdrawn, the substance exited the category list because there was nothing left in the process to track. Compounding pharmacies cannot legally produce it under Section 503A. The removal didn't open a door; it confirmed the pathway had closed. The part most often missing from telehealth marketing in October 2026 is what happened in December 2024, when the FDA's Pharmacy Compounding Advisory Committee evaluated the compound for 503A list inclusion, and what [the FDA's regulatory framework for bulk drug compounding](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks) says about what that review process is designed to assess.

The molecule

it's a fragment of human growth hormone designed to target fat without the rest of the hormone

AOD-9604 is a synthetic analog of the C-terminal fragment of human growth hormone — specifically, amino acids 176 through 191 of the GH sequence. Growth hormone's metabolic effects are not uniform: different portions of the molecule engage different receptor pathways with different downstream consequences. The hypothesis behind AOD-9604 was that you could isolate the lipolytic activity — the fat-mobilization signal — and deliver it without engaging the anabolic and insulin-sensitizing pathways that create the complexity associated with full GH therapy. A targeted fragment would theoretically produce the metabolic effect without the downstream side-effect profile of the whole hormone. [The PubMed literature trail for AOD-9604](https://pubmed.ncbi.nlm.nih.gov/?term=AOD-9604) includes preclinical animal studies that showed lipid mobilization consistent with this hypothesis. In rodent models, the fragment moved fat metabolism markers without triggering the insulin-pathway effects associated with the intact hormone. This preclinical signal was strong enough to attract serious pharmaceutical development. That's the first chapter of the AOD-9604 story. The second chapter is what happened when it was tested in humans at the scale of a clinical efficacy trial.

The pitch

the fat-loss-without-side-effects angle is coherent — the clinical development outcome is not

The AOD-9604 pitch in October 2026 is specific and consistent: GH fragment, fat metabolism targeting, none of the insulin effects or growth effects that complicate full GH therapy. It shows up alongside GLP-1 alternatives in optimization-clinic materials, sometimes framed as a lower-cost route to body composition change for patients who want something with a different profile than semaglutide. The mechanistic premise is not absurd — isolating a lipolytic signal from a large multi-functional hormone is a coherent pharmaceutical hypothesis, and the preclinical evidence supported it. What the pitch omits is the clinical development outcome. AOD-9604 was not a fringe supplement project. It was a licensed pharmaceutical development program: Metabolic Pharmaceuticals advanced it through Phase I and Phase II trials because the preclinical rationale was strong enough to warrant the investment. The Phase 2b trial — the test designed to show that the mechanism produced actual clinical benefit in people — produced a result that ended the obesity development program entirely. That result is not a contested interpretation or a preliminary finding. It is a completed trial with a published endpoint and a program termination decision that followed it.

What the data says

536 people, 24 weeks, no significant weight loss over placebo — and the development program stopped

The pivotal human study for AOD-9604 was a 24-week randomized controlled obesity trial enrolling 536 participants — a properly sized efficacy test for the indication the molecule was developed to address. The result: no statistically significant weight loss compared with placebo. The obesity development program was terminated in 2007. [The ClinicalTrials.gov registration history for AOD-9604](https://clinicaltrials.gov/search?term=AOD-9604) reflects a clinical program that produced Phase I safety and tolerability data and a Phase 2b efficacy result that closed the obesity application. Phase I confirmed the compound is tolerated and produces measurable changes in lipid metabolism markers — consistent with the mechanism, and the data most often cited by clinic marketing. Phase 2b confirmed that those measurable metabolic changes do not translate into meaningful weight loss in people under controlled trial conditions. Both results are in the public record. The online fat-loss narrative about AOD-9604 is built almost entirely on the Phase I signal and the preclinical mechanism story. [A PubMed literature search for AOD-9604](https://pubmed.ncbi.nlm.nih.gov/?term=AOD-9604) contains both the positive Phase I pharmacology and the negative Phase 2b outcome. The proportion in which each appears in telehealth marketing materials in October 2026 is not representative of what the combined data shows.

Early human — PeptideFactCheck stance

the evidence tier is real — what it says about fat loss runs opposite to the marketing

AOD-9604 holds PeptideFactCheck's Early human evidence tier. That places it above purely anecdotal or preclinical-only compounds: human studies exist, metabolic signals were measured in Phase I participants, and the pharmacology was real. Early human means the evidence is not mature — and in this specific case, maturity means a completed efficacy trial with 536 participants that produced a negative result. The evidence-tier definition is: small, preliminary, or narrow human studies exist, but the evidence is not mature. The AOD-9604 situation inverts the usual uncertainty. The uncertainty here is not whether a human trial exists. It is that the human trial exists, was properly powered, and did not demonstrate the outcome the marketing asserts. The December 2024 PCAC process reviewed AOD-9604 for 503A Bulks List inclusion — materials from [the FDA's December 4, 2024 PCAC meeting](https://www.fda.gov/advisory-committees/advisory-committee-calendar/december-4-2024-meeting-pharmacy-compounding-advisory-committee-12042024) are in the public record. The nomination was withdrawn rather than advanced. FDA removed AOD-9604 from the Category 2 interim tracking list in April 2026 — that removal is the end of a regulatory thread, not the beginning of a cleared pathway. Interesting enough to watch for future research directions. Too early for the certainty the current pitch delivers. Source trail before certainty.

Editorial boundary

What this page will not do

It will not provide dosing, cycling, sourcing, injection, or personal medical instructions. The job is to classify claims and explain mechanisms.